| Celularity Announces Full Year 2024 Operating and Financial Results |
Net revenues for the year ending December 31, 2024, totaled $54.2 million, an increase of $31.4 million, or 138.1%, compared to the previous year. Net revenues for the year ending December 31, 2024, totaled $54.2 million, an increase of $31.4 million, or 138.1%, compared to the previous year. |
globenewswire.com |
2025-05-09 13:15:00 |
Czytaj oryginał (ang.) |
| Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees |
FLORHAM PARK, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a cellular and regenerative medicine company, today announced that Nasdaq has notified the Company that it has not paid certain fees required by Listing Rule 5250(f) and accordingly the Company will be delisted unless it appeals this determination. The Company's past due fee balance totaled $70,000. On April 25, 2025, the Company paid in full the fee balance owed to Nasdaq. |
globenewswire.com |
2025-04-25 21:30:00 |
Czytaj oryginał (ang.) |
| Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products |
Action delays to January 1, 2026, the effective date of a Biden-era Medicare LCD for skin substitute products used to treat diabetic foot ulcers and venous leg ulcers Action delays to January 1, 2026, the effective date of a Biden-era Medicare LCD for skin substitute products used to treat diabetic foot ulcers and venous leg ulcers |
globenewswire.com |
2025-04-14 12:00:00 |
Czytaj oryginał (ang.) |
| Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products |
Natalin and Acelagraft™ are the latest additions to Celularity's portfolio of HCT/P 361 products for use in the treatment of partial and full thickness acute and chronic wounds Natalin and Acelagraft™ are the latest additions to Celularity's portfolio of HCT/P 361 products for use in the treatment of partial and full thickness acute and chronic wounds |
globenewswire.com |
2025-02-25 10:00:00 |
Czytaj oryginał (ang.) |
| Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company |
FLORHAM PARK, N.J., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a cellular and regenerative medicine company, today announced that it has entered into a Master Services Collaboration Agreement with BlueSphere Bio, Inc. (BSB) covering manufacturing activities for certain BSB cell therapy products. |
globenewswire.com |
2025-02-24 10:00:00 |
Czytaj oryginał (ang.) |
| Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter |
FLORHAM PARK, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today announced that it has received a letter from the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”), confirming that Celularity has regained compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”). Following the filing of its Quarterly Report on Form 10-Q for the period ended September 30, 2024, Nasdaq has determined that the matter is now closed. |
globenewswire.com |
2024-12-10 10:00:00 |
Czytaj oryginał (ang.) |
| Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023 |
FLORHAM PARK, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today announced that it filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024. With this filing, the Company is now current on its quarterly report filings. |
globenewswire.com |
2024-12-06 10:00:00 |
Czytaj oryginał (ang.) |
| Celularity Inc. Announces Receipt of Nasdaq Notification |
FLORHAM PARK, N.J., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced that on November 21, 2024, the Company received notification from the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company does not comply with the Nasdaq continued listing requirements due to the Company's inability to timely file its Quarterly Report on Form 10-Q for the period ended September 30, 2024 (the “Q3 Form 10-Q”). Nasdaq's notice has no immediate effect on the listing of Celularity's common stock and warrants, which continue to trade on the Nasdaq Capital Market under the symbols “CELU” and “CELUW,” respectively. |
globenewswire.com |
2024-11-27 19:00:00 |
Czytaj oryginał (ang.) |
| Celularity's Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia Pacific |
FLORHAM PARK, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company, today announced that its strategic partner, Genting Berhad, has broken ground on Fontaine Vitale, a state-of-the-art stem cell and regenerative medicine facility in the Sanur Special Economic Zone located in Bali, Indonesia. Fontaine Vitale will offer world-class cell therapies focused on wellness, aesthetics, and regenerative medicine to both local and international patients using placenta-derived stem cells manufactured by Celularity in its US facility, according to Genting Berhad's press release. The new center is expected to commence commercial operations towards the end of 2026. |
globenewswire.com |
2024-11-20 10:30:00 |
Czytaj oryginał (ang.) |
| Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter |
FLORHAM PARK, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company, today announced that the Nasdaq Listing Qualifications Hearings Panel (the “Hearings Panel”) has cancelled the previously scheduled hearing regarding Celularity's non-compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), as the Company has cured its filing delinquency. The matter is now closed, and Nasdaq has confirmed that Celularity's stock will continue to be listed and traded on The Nasdaq Stock Market. |
globenewswire.com |
2024-11-18 10:30:00 |
Czytaj oryginał (ang.) |
| Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel |
Celularity common stock and warrants will continue to trade on The Nasdaq Capital Market under the symbols “CELU” and “CELUW,” respectively Celularity common stock and warrants will continue to trade on The Nasdaq Capital Market under the symbols “CELU” and “CELUW,” respectively |
globenewswire.com |
2024-10-23 12:30:00 |
Czytaj oryginał (ang.) |
| Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal |
FLORHAM PARK, N.J., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a regenerative medicine company developing and commercializing placental-derived technologies, today announced that it has received a formal notice from the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) on October 16, 2024, indicating that the Company is subject to delisting due to its inability to timely file its Forms 10-Q for the the periods ended March 31, 2024, and June 30, 2024 (the “Forms 10-Q”) within the prescribed 180-day compliance period. Nasdaq's notice has no immediate effect on the listing of the Company's common stock and warrants, which continue to trade on the Nasdaq Capital Market under the symbols “CELU” and “CELUW”, respectively. |
globenewswire.com |
2024-10-18 22:00:00 |
Czytaj oryginał (ang.) |
| Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc. |
FLORHAM PARK, N.J., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company, today announced that it had added to its commercial portfolio of placental-derived advanced biomaterial products with the acquisition of Rebound, a full thickness placental-derived allograft matrix product, from Sequence LifeScience, Inc. (“Sequence”). |
globenewswire.com |
2024-10-16 21:15:00 |
Czytaj oryginał (ang.) |
| Celularity to Present at H.C. Wainwright's 26th Annual Global Investment Conference |
FLORHAM PARK, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, today announced that Robert J. Hariri, M.D., Ph.D., Chairman, CEO and founder, will present at H.C. Wainwright's 26th Annual Global Investment Conference being held at the Lotte New York Palace Hotel in New York City on September 9-11, 2024. |
globenewswire.com |
2024-09-05 20:05:00 |
Czytaj oryginał (ang.) |
| Celularity Appoints Richard J. Berman to its Board of Directors |
Seasoned Public Company Director and Finance Veteran Brings Extensive Track Record of Success in Facilitating the Growth of Shareholder Value Seasoned Public Company Director and Finance Veteran Brings Extensive Track Record of Success in Facilitating the Growth of Shareholder Value |
globenewswire.com |
2024-08-28 20:45:00 |
Czytaj oryginał (ang.) |
| Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing |
FLORHAM PARK, N.J., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced that on August 22, 2024, the Company received notification from the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Form 10-Q for the quarter ended June 30, 2024 (“Q2 2024 Form 10-Q”), and because the Company remains delinquent in filing its Form 10-Q for the quarter ended June 30, 2024 (“Q2 2024 Form 10-Q”), it does not comply with the Nasdaq continued listing requirements which require listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission. Nasdaq's notice has no immediate effect on the listing of Celularity's common stock and warrants, which continue to trade on the Nasdaq Capital Market under the symbols “CELU” and “CELUW”, respectively. |
globenewswire.com |
2024-08-23 21:00:00 |
Czytaj oryginał (ang.) |
| Celularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announces First Half 2024 Expected Combined Net Sales of $26.9 Million Representing 290% Growth Over First Half 2023 |
FLORHAM PARK, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”) a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, today announced its 2023 full-year reported combined net sales of its advanced biomaterial product and biobanking businesses and announced first half 2024 expected combined net sales. As used here, “net sales” refers to direct-customer and distributor product sales of advanced biomaterial products and biobanking services, respectively, and does not include any revenue from other sources such as fees or revenue earned under research collaboration agreements. |
globenewswire.com |
2024-07-31 12:30:00 |
Czytaj oryginał (ang.) |
| Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting |
FLORHAM PARK, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity”), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that it presented in vivo data from its T-cell therapy platform at this year's ASCO Annual Meeting in Chicago. |
globenewswire.com |
2024-06-03 12:38:00 |
Czytaj oryginał (ang.) |
| Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing |
FLORHAM PARK, N.J., May 24, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that on May 21, 2024, the Company received notification from the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Form 10-Q for the quarter ended March 31, 2024 (“Q1 2024 Form 10-Q”), and because the Company remains delinquent in filing its Annual Report on Form 10-K for the year ended December 31, 2023 (“2023 Form 10-K”), does not comply with the Nasdaq continued listing requirements which require listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission. Nasdaq's notice has no immediate effect on the listing of Celularity's common stock and warrants, which continue to trade on the Nasdaq Capital Market under the symbols “CELU” and “CELUW”, respectively. |
globenewswire.com |
2024-05-24 21:15:00 |
Czytaj oryginał (ang.) |
| Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy |
Placental T Cells Demonstrated Greater Persistence, Resistance to Exhaustion and Efficacy Compared To Peripheral Blood Mononuclear Cells Placental T Cells Demonstrated Greater Persistence, Resistance to Exhaustion and Efficacy Compared To Peripheral Blood Mononuclear Cells |
globenewswire.com |
2024-05-14 13:15:00 |
Czytaj oryginał (ang.) |
| Celularity Inc. to Host Investor and Analyst Research & Development Day |
Event Will Be Hosted On-site and Aired Virtually Highlighting Research, Clinical and Commercial Progress Event Will Be Hosted On-site and Aired Virtually Highlighting Research, Clinical and Commercial Progress |
globenewswire.com |
2024-04-22 12:00:00 |
Czytaj oryginał (ang.) |
| Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing |
FLORHAM PARK, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (the “Company”), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that on April 17, 2024, the Company received notification from the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Annual Report on Form 10-K for the year ended December 31, 2023, it is no longer in compliance with Nasdaq's continued listing requirements which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission. Nasdaq's notice has no immediate effect on the listing of Celularity's common stock and warrants, which continue to trade on the Nasdaq Capital Market under the symbols “CELU” and “CELUW,” respectively. |
globenewswire.com |
2024-04-19 21:30:00 |
Czytaj oryginał (ang.) |
| Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024 |
FLORHAM PARK, N.J., April 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, today announced that its abstract entitled “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” was accepted by the Orthopedic Research Society (ORS) Tendon Conference, which will be held from May 30 - June 1, 2024 at the Mayo Clinic in Rochester, MN. The conference theme is “Mechanism to Therapy - Emerging Technologies and Therapeutic Outcomes.” |
globenewswire.com |
2024-04-18 20:30:00 |
Czytaj oryginał (ang.) |
| Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products |
CELU Announces Net Sales Trending Ahead of Expectations for 1Q '24; Implements Planned '24 SG&A Reductions & Mfg. Ramp for Advanced Biomaterial Products |
globenewswire.com |
2024-04-15 12:00:00 |
Czytaj oryginał (ang.) |
| Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells |
FLORHAM PARK, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that it will present in vitro data from its investigational natural killer (NK) cell therapy programs at this year's American Society of Gene and Cell Therapy (ASGCT) Annual Meeting. |
globenewswire.com |
2024-04-08 13:00:00 |
Czytaj oryginał (ang.) |